Cargando…

Elbasvir/Grazoprevir, an Alternative in Antiviral Hepatitis C Therapy in Patients under Amiodarone Treatment

A sofosbuvir/ledipasvir combination is part of a first-line treatment of hepatitis C. However, in patients concurrently treated with amiodarone, cardiac side effects have been described, resulting in an official warning in 2015 by the American Food and Drug Administration and the European Medicines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiss, Lina, Wustmann, Kerstin, Semmo, Mariam, Schwerzmann, Markus, Semmo, Nasser
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2018
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869552/ https://www.ncbi.nlm.nih.gov/pubmed/29606942 http://dx.doi.org/10.1159/000486951

Ejemplares similares

A Hepatitis C Virus-Associated Chronic Hepatitis Patient Developing Various Adverse Events Including Severe Gingivitis, Gingival Bleeding, and Inflammation of Genital Vulva during the Course of Antiviral Therapy with Elbasvir/Grazoprevir
por: Tarao, Kazuo, et al.
Publicado: (2017)

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
por: Bell, Allison M., et al.
Publicado: (2016)

Safety and efficacy of elbasvir/grazoprevir for the treatment of chronic hepatitis C: current evidence
por: Morikawa, Kenichi, et al.
Publicado: (2018)

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients
por: Ji, Qinghua, et al.
Publicado: (2021)

Spotlight on grazoprevir–elbasvir once-daily combination and its potential in the treatment of hepatitis C
por: Suraweera, Duminda, et al.
Publicado: (2016)

Patient-reported outcomes in individuals with hepatitis C virus infection treated with elbasvir/grazoprevir
por: Ng, Xinyi, et al.
Publicado: (2018)

No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole
por: Feng, H‐P, et al.
Publicado: (2017)

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
por: Liu, Jinyu, et al.
Publicado: (2022)

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
por: Chen, Jin, et al.
Publicado: (2020)

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
por: Zhdanov, Konstantin, et al.
Publicado: (2020)

Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C–Viremic Donor to Uninfected Recipient Kidney Transplantation
por: Sise, Meghan E., et al.
Publicado: (2020)

Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function
por: Eisenberger, Ute, et al.
Publicado: (2018)

Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
por: Liu, Chen-Hua, et al.
Publicado: (2020)

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy
por: Hézode, Christophe, et al.
Publicado: (2019)

An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
por: Lee, Youn Jae, et al.
Publicado: (2019)

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
por: Puenpatom, Amy, et al.
Publicado: (2020)

The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan
por: Tsai, Tzu‐Cheng, et al.
Publicado: (2019)

Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
por: Yao, Yinan, et al.
Publicado: (2017)

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy
por: Sulejmani, Nimisha, et al.
Publicado: (2018)

Elbasvir/grazoprevir in Asia‐Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection
por: George, Jacob, et al.
Publicado: (2018)

Efficacy and safety of elbasvir/grazoprevir in treatment‐naive Chinese adults with hepatitis C virus infection: A randomized trial
por: Wei, Lai, et al.
Publicado: (2020)

Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study
por: Jang, Eun Sun, et al.
Publicado: (2021)

Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China
por: Liu, Jinyu, et al.
Publicado: (2021)

Safety and efficacy of elbasvir/grazoprevir in patients infected with hepatitis C virus genotype 4 in Qassim region of Saudi Arabia
por: Murgod, Shivananda E., et al.
Publicado: (2023)

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study
por: Jacobson, Ira M., et al.
Publicado: (2019)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

Efficacy and Safety of Elbasvir/Grazoprevir in Hepatitis C Virus GT1- and GT4-Infected People Aged 65 Years or Older
por: Flamm, Steven, et al.
Publicado: (2019)

Pharmacokinetic similarity demonstrated after crushing of the elbasvir/grazoprevir fixed-dose combination tablet for HCV infection
por: Pijnenburg, Daniëlle W M, et al.
Publicado: (2020)

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
por: Li, Haiyan, et al.
Publicado: (2020)

Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection
por: Reau, Nancy, et al.
Publicado: (2017)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
por: Kumada, Hiromitsu, et al.
Publicado: (2016)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry
por: Hinrichsen, Holger, et al.
Publicado: (2020)

Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France
por: Maunoury, Franck, et al.
Publicado: (2018)

Real‐world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group
por: Mashiba, Toshie, et al.
Publicado: (2019)

Amiodarone-Induced Acute Liver Injury
por: Essrani, Rajesh, et al.
Publicado: (2020)

Elbasvir/grazoprevir in children aged 3–18 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study
por: Gonzalez-Peralta, Regino P., et al.
Publicado: (2023)

A Retrospective Cohort Study: Safety and Effectiveness of Elbasvir/Grazoprevir ± Ribavirin Compared With Ombitasvir/Paritaprevir/Ritonavir/Dasabuvir ± Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection
por: Hung, Hsuan-Yu, et al.
Publicado: (2021)

Robust Regression Analysis of GCMS Data Reveals Differential Rewiring of Metabolic Networks in Hepatitis B and C Patients
por: Simillion, Cedric, et al.
Publicado: (2017)

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial
por: Grebely, Jason, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bte6f9ns5a9m4tte03bd0sk2n6